The hematopoietic stem cell in myelodysplasia

Stem Cells

Volumn 22, Issue 4, 2004, Pages 590-599

  Liesveld, Jane L ^a,b   Jordan, Craig T ^a   Phillips II, Gordon L ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Apoptosis; Myelodysplasia; Progenitor cells

Indexed keywords

AMIFOSTINE; CIPROFLOXACIN; CYCLOSPORIN A; DEXAMETHASONE; INFLIXIMAB; INTERLEUKIN 6; PENTOXIFYLLINE; THALIDOMIDE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DNA MODIFICATION; DRUG MECHANISM; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOMODULATION; MICROENVIRONMENT; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PURIFICATION; SIGNAL TRANSDUCTION; STROMA CELL;

EID: 3543010174     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.22-4-590     Document Type: Article

References (85)

1. Vardiman JW, Harris N, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
2. Lichtman MA. The stem cell in the pathogenesis and treatment of myelogenous leukemia: a perspective. Leukemia 2001;15:1489-1494.
3. Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia 2002;16:559-562.
4. Guzman ML, Upchurch D, Grimes B et al. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood 2001;94:2177-2179.
5. Blair A, Hogge DE, Ailles LE et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997;89:3104-3112.
6. -. Blood 1998;92:4325-4335.
7. Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (GD117). Exp Hematol 2000;28:660-671.
8. Green CL, Loken M, Buck D et al. Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Leukemia 2000;14:770-772.
9. Nilsson L, Grundstrom I, Arvidsson I et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000;96:2012-2021.
10. Von Lom K, Hagenmeijer A, Smit E et al. Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. Leukemia 1995;9:1818-1821.
11. Saitoh K, Miura I, Takahashi N. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes. Blood 1998; 92:2886-2892.
12. Miura I, Kobayashi Y, Takahashi N et al. Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting. Br J Haematol 2000;110:876-879.
13. Amin HM, Jilani I, Estey EH et al. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 2003;102:1866-1868.
14. Benito AL, Bryant E, Loken MR et al. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. Leuk Res 2003;27:425-436.
15. Hirai H. Molecular mechanisms of myelodysplastic syndrome. Jpn J Clin Oncol 2003;33:153-160.
16. Xie D, Hofmann WK, Mori N et al. Allelotype analysis of the myelodysplastic syndrome. Leukemia 2000;14:805-810.
17. Mori N, Morosetti R, Hoflehnere E et al. Allelic loss in the progression of myelodysplastic syndrome. Cancer Res 2000;60:3039-3042.
18. Kaeferstein A, Drug U, Tiesmeier J et al. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML. Leukemia 2003;17:343-349.
19. Au W, Fung A, Man C, et al. Aberrant p 15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. Br J Haematol 2003; 120:1062-1065.
20. Uchida T, Kinoshita T, Nagai H et al. Hypermethylation of the p15INK4b gene in myelodysplastic syndromes. Blood 1997;90:1403-1409.
21. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15(INK4B) is common, is associated with deletion of genes on chromosome are 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003;17:1813-1819.
22. Quesnel B, Guillerm G, Verecque R et al. Methylation of the p15INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998;91:2985-2990.
23. Teofili L, Martini M, Di Mario A et al. Expression of p15ink4b gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic pogenitors. Blood 2001;98:495-497.
24. Fuchigami K, Mori H, Matsuo T et al. Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry. Leuk Res 2000;24:163-174.
25. Vehmeyer K, Haase D, Alves F. Increased peripheral stem cell pool in MDS: an indication of disease progression? Leuk Res 2001;25:955-959.
26. ++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia. Br J Haematol 2003;121:63-75.
27. Cilloni D, Gottardi E, Messa F et al. Significant correlation between the degree of WT1 expression and the international prognostic scoring system score in patients with myelodysplastic syndromes. J Clin Oncol 2003;21:1988-1995.
28. Lepelley P, Foulani S, Grardel N et al. Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes. Leuk Lymph 1998;29:547-551.
29. + cells from normal and myelodysplastic bone marrow. Blood 2002;100:3553-3560.
30. Miyazato A, Ueno S, Ohmine K et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 2001;98:422-427.
31. Ohyashiki JH, Sashida G, Tauchi T et al. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002; 21:680-687.
32. Kuramoto K, Ban S, Oda K et al. Chromosomal instability and radiosensitivity in myelodysplastic syndrome cells. Leukemia 2002;16:2253-2258.
33. Ueda M, Ota J, Yamashita Y et al. DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome. Br J Haematol 2003;123:288-296.
34. Osterveld M, de Witte T. Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia. Blood Rev 2000; 14:182-189.
35. Aivado M, Gattermann N, Bottomley S. X chromosome inactivation ratios in female carriers of X-linked sideroblastic anemia. Blood 2001;97:4000-4002.
36. Bouscary D, Chen YL, Guesnu M. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp Hematol 2000;28:784-791.
37. Shimazaki K, Ohshima K, Suzumiya J et al. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br J Haematol 2000;110:584-590.
38. Washington LT, Jilani I, Estey E, Albitar M. Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia. Leuk Res 2002;26:899-902.
39. Albitar M, Manshouri T, Shen Y et al. Myelodysplastic syndrome is not merely "preleukemia." Blood 2002; 100:791-798.
40. Pecci A, Travaglino E, Kiersy C et al. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow. Acta Haematol 2003;109:29-34.
41. + myelodysplastic cells is associated with intracellular redox chages and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997;99:625-631.
42. Lin CW, Manshouri T, Jilani I et al. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res 2002;26:551-559.
43. Huh YO, Jilani I, Estey E et al. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Leukemia 2002;16:2249-2252.
44. Yoshida Y. The aplasia-myelodysplasia enigma: a reemerging question. Int J Hematol 1999;70:65-67.
45. Parker JE, Mufti GJ. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol 2001;73:416-428.
46. Boudard D, Vasselon C, Bertheas MF et al. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol 2002;70:115-125.
47. Parker JE, Mufti GJ, Rasool F et al. The role of apoptosis, proliferation, and the Bcl-2 related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000;96:3932-3938.
48. Hellstrom-Lindberg E, Schmidt-Mende J, Forsblom AM et al. Apoptosis in refractory anemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Heamatol 2001;112:714-726.
49. Schmidt-Mende J, Tehranchi R, Forsblom AM et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 2001;15:742-751.
50. Tehranchi R, Fadell B, Forsblom AM et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003;101:1080-1086.
51. Gattermann N. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res 2000;24:141-151.
52. Plasilova M, Zivny J, Jelinek J et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002;16:67-73.
53. Sawanobori M, Yamaguchi S, Hasegawa M et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003;27:583-591.
54. Shetty V, Hussaini S, Broady-Robinson L et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 2000;15:1388-1392.
55. Stasi R and Amadori S. Infliximab chimeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol 2002;116:334-337.
56. Novitzky N, Mohamed R, Finlayson J et al. Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes. Exp Hematol 2000;28:941-949.
57. Rosenfeld C, Bedell C. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR: Fc) in patients with low risk myelodysplastic syndrome. Leuk Res 2002;26:721-724.
58. Muller A, Lange K, Gaiser T et al. Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. Leuk Res 2002;26:163-168.
59. Soligo D, Servida F, Delia D et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant hematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001;113:126-135.
60. Morgan MA, Dopl O, Reuter CW. Cell-cycle-dependent activation of mitogen-activated protein kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of Ras signaling. Blood 2001;14:1823-1834.
61. Parker J, Mufti GJ. Ras and myelodysplasia: lessons from the last decade. Semin Hematol 1996;33:206.
62. Scheele JS, Ripple D, Lubbert M. The role of ras and other low molecular weight guanine nucleotide (GTP)-grinding proteins during hematopoeitic cell differentiation. Cell Mol Life Sci 2000;57:1950-1963.
63. Kalina U, Hofmann WK, Koschmieder Set al. Alteration of c-mp1-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes. Exp Hematol 2000;28:1158-1163.
64. Hoefsloot LH, van Amelsvoort MP, Broeders LCAM et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood 1997; 89:1690-1700.
65. + aplastic anemia and myelodysplasia. Br J Haematol 2000;108:582-591.
66. Kochenderfer JN, Kobayashi S, Wieder ED, Su C et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002;100:3639-3645.
67. Alvado M, Rong A, Stadler M et al. Favorable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a "non-clonal" pattern of X-chromosome inactivation in bone marrow cells. Euro J Haematol 2002;68:210-216.
68. Saunthararajah Y, Nakamura R, Nam JM et al. HLA-DR15 (DR2) is over represented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:1570-1574.
69. Sloand EM, Kim S, Fuhrer M et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002;100:4427-4432.
70. + V-beta-restricted T cells in patients with trisomy 8 myelodysplasia. Blood 2002;100:166a.
71. Ma L, Delforge M, Verhoef GEG et al. The immunophenotype and function of dendritic cells in myelodysplastic syndromes. Blood 2002;100:166a.
72. Moldrem J, Jiang Y, Stetler-Stevenson M et al. Hematologic response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T cell receptor Vβ profiles. Br J Haematol 1998;102:1314.
73. Culligan DJ, Cachia P, Whittaker A et al. Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 1992;81:346.
74. Tauro S, Hepburn MD, Peddie CM et al. Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 2002;16:785-790.
75. Tennant GB, Walsh V, Truran LN et al. Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. Br J Haematol 2000;111:953-962.
76. Alvi S, Shaher A, Shetty V et al. Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes. Leuk Res 2001; 25:941-954.
77. Flores-Figueroa E, Gutierrez-Espindola G, Montesions JJ, et al. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 26:2002;677-686.
78. Hu X, Zuckermann KS. Transforming growth factor: signal transduction pathways, cell cycle mediation, and effects on hematopoiesis. J Hematother Stem Cell Res 2001;10:67-74.
79. Brunner B, Gunsilius E, Schumacher P et al. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res 2002; 11:119-125.
80. Bellamy WT, Richter L, Sirjani D et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427-1434.
81. Curly CR, Spencer CM. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndromes. Drugs 2001;61:641-684.
82. Galanopoulos A, Kritidou-Griva E, Gligori J et al. Treatment of patients with myelodysplastic syndrome with amifostine. Leuk Res 2001;25:665-671.
83. List AF. New approaches to the treatment of myelodysplasia. The Oncologist 2002;7:39-49.
84. Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndrome: implications for new therapies. Leukemia 2000;14:2-8.
85. Stover JA, Lejeune C, Stevernson D et al. Molecular class prediction of progression to acute myeloid leukemia in patients with myelodysplastic syndromes. Proc AACR 2003;44:923,4033a.